Miravo Healthcare™ Announces Third Quarter 2022 Results Release Date and Conference Call Details

Rhea-AI Summary

Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF), operating as Miravo Healthcare, will announce its third quarter 2022 financial results on November 14, 2022, before market opening. A conference call will be held the same day at 11:00 a.m. ET, featuring President & CEO Jesse Ledger and senior management. Investors can join via dial-in numbers 416 764 8646 or 1 888 396 8049, with audio webcast available for replay. Miravo focuses on in-licensing and acquiring products across therapeutic areas, aiming for growth in Canadian and international markets.

Positive

• Company's strategy focuses on growth-oriented product in-licensing and acquisitions.
• Targeting multiple therapeutic areas including pain and neurology indicates diversified market presence.

Negative

• None.

MISSISSAUGA, Ontario,--(BUSINESS WIRE)-- Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, today announced it expects to release its third quarter 2022 financial results before markets open on Monday, November 14, 2022.

The Company will subsequently hold a conference call the same day, Monday, November 14, 2022 at 11:00 a.m. ET, hosted by Jesse Ledger, Miravo’s President & Chief Executive Officer and other senior management. A question-and-answer session will follow the corporate update.

CONFERENCE CALL DETAILS

DATE: Monday, November 14, 2022

TIME: 11:00 a.m. ET

DIAL-IN NUMBERS: 416 764 8646 or 1 888 396 8049

The audio webcast and webcast replay can be accessed at:

https://app.webinar.net/l5OL6w01yAn

About Miravo Healthcare

Miravo is a Canadian-focused, healthcare company with global reach and a diversified portfolio of commercial products. The Company’s products target several therapeutic areas, including pain, allergy, neurology and dermatology. The Company’s strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets. Miravo’s head office is located in Mississauga, Ontario, Canada, the international operations are located in Dublin, Ireland and the Company’s manufacturing facility is located in Varennes, Québec, Canada. For additional information, please visit www.miravohealthcare.com.

FOR MORE INFORMATION, PLEASE CONTACT:

View source version on businesswire.com: https://www.businesswire.com/news/home/20221031005243/en/

Investor Relations

905 673-6980 / option 2

ir@miravohealth.com

Source: Nuvo Pharmaceuticals Inc.

FAQ

When will Miravo Healthcare release its Q3 2022 financial results?

Miravo Healthcare will release its Q3 2022 financial results on November 14, 2022.

What time is the Miravo Healthcare conference call on November 14, 2022?

The conference call is scheduled for 11:00 a.m. ET on November 14, 2022.

How can I access the audio webcast for Miravo Healthcare's Q3 2022 results?

The audio webcast can be accessed through their official website or via the provided link in the press release.

Who will host the conference call for Miravo Healthcare's Q3 results?

The conference call will be hosted by Jesse Ledger, President & CEO of Miravo Healthcare.

What are the dial-in numbers for Miravo Healthcare's Q3 conference call?

The dial-in numbers are 416 764 8646 or 1 888 396 8049.